A one year, open label, multi-center, extension study to CHTF919D2301 to assess the long term safety of tegaserod 6 mg bid given orally in female patients with symptoms of dyspepsia

Registry ID

EUCTR2004-002612-28

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharmaceuticals UK Ltd

Start date

2004-11-17

Completion date

2006-08-04

Last update

2026-08-16

Conditions

• dyspepsia

Summary

To evaluate the long gterm safety of tegaserod (6mg bid) at 6 months in female patients with symptoms of dyspepsia

Locations

• , , UK

View on source registry